1. Cheung NK, Guo H, Hu J, et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology. 2012;1(4):477–86.
2. US Food & Drug Administration. FDA grants accelerated approval to naxitamab for high-risk neuroblastoma in bone or bone marrow [media release]. 27 Nov 2020. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow.
3. Y-mAbs Therapeutics Inc. DANYELZA® (naxitamab-gqgk) injection, for intravenous use): US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf. Accessed 27 Nov 2020.
4. Therapeutics Ym. Y-mAbs Therapeutics, Inc. joins forces with Cancer Center to break new ground on immunotherapy [media release]. 14 Oct 2015. http://www.ymabs.com.
5. Therapeutics Ym. Y-mAbs Therapeutics, Inc. enters into development and manufacturing agreement for antibody compound with Patheon Biologics [media release]. 2 Dec 2015. http://www.ymabs.com.